Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
137.5 USD | -0.30% | +2.28% | +31.27% |
May. 07 | TD Cowen Adjusts Price Target on DaVita to $139 From $136 | MT |
May. 03 | UBS Adjusts Price Target on DaVita to $169 From $145, Maintains Buy Rating | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+31.27% | 12.06B | B- | ||
+20.68% | 85.55B | C+ | ||
-29.31% | 70.07B | B- | ||
+9.65% | 29.06B | C+ | ||
-8.63% | 17.51B | B | ||
+2.14% | 17.39B | A- | ||
+0.39% | 15.38B | A- | ||
+6.47% | 13.4B | B- | ||
+68.09% | 12.87B | C- | ||
+6.43% | 12.77B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DVA Stock
- Ratings DaVita Inc.